Exclusive: Sudo Biosciences secures $116M to start trials of its oral and topical TYK2 candidates
Sudo Biosciences has raised a $116 million Series B from well-known investors and Sanofi’s VC arm, the transatlantic biotech told Endpoints News, as it looks to capitalize on the TYK2 field following the lead of Bristol Myers Squibb and Takeda (by way of Nimbus Therapeutics).
Carmel, IN-based Sudo is attempting to carve a niche in the TYK2 space by creating a brain-penetrant oral drug that could potentially treat conditions such as multiple sclerosis, which hits close to home for CEO Scott Byrd, whose wife has lived with the disease “for the better part of her life,” he said in an interview.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.